3Martikainen J, Kivi I, Linnosmaa I. European Prices prices of newly lanched reimbursable pharmaceuticals-a pilot study. Health Policy 2005;74(3) : 235-46.
4Ess SM, Schneeweiss S, Szucs TD. European heahhcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21(2). 89-103 .
5Gamttini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis, Health Policy 2007;82:330-9.
6Danzon PM, Kim JD. International price comparisons for pharmaceuticals. Measurement and policy issues. Pharmacoeconomics 1998 , 14(Suppl. 1) : 115-28.
7Danzon PM,Chao L-W. Cross national price differences for pharmaceuticals, how large and why? Journal of Health Economics 2000 , 19 : 159-95.
8Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000;51(3) : 149-62.
2Josh J. Carlson, Sean D. Sullivan. Linking Payment to Health Outcomes: A Taxonomy and Examination of Performance-based Reimbursement Schemes between Heahhcare Payers and Manufacturers[J]. Health Policy, 2010, 96 ( 3 ) : 179-190.
3Jaime Espin, Joan Rovira. Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines[R]. Escuela Andsaluza de Salud P6blica, 2011.
4黄伟.我国药品谈判结果实施模式研究[D].沈阳:沈阳药科大学,2012.
5Espin J. Analysis of Diffrences and Commnonalities in Prcing and Reimbursement in Europe[R]. 2007.
6中国药学会药物经济学专业委员会“协议定价”课题组.医保药品协议定价:理论与实践[R].2010.
7Nathalie Grandls. Drug Price Setting And Regulation in France[R]. Institute for Research and Documentation in Health Economics, September 2008.
